Subsequent to 2017 when the aforementioned meta-analysis by Arnold and colleagues was published [20], the results of which were later confirmed by the PARADIGM study [19], patients with a wild-type RAS mCRC tumor have generally been treated with a combination of chemotherapy and an anti-EGFR agent. This evidence concerns the gene EGFR and neoplasm.